Quarterly report [Sections 13 or 15(d)]

License Agreements (R&D and Journey) (Details)

v3.25.3
License Agreements (R&D and Journey) (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 02, 2025
Dec. 31, 2024
Apr. 30, 2024
Jan. 31, 2022
Jun. 30, 2021
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
License Agreements                  
Expense recognized for licenses acquired           $ 0 $ 0 $ 0 $ 0
Revenues           17,631 $ 14,629 47,183 $ 42,555
Other revenue           606   2,010  
VYNE Product Acquisition                  
License Agreements                  
Deferred cash payment       $ 5,000          
VYNE Product Acquisition                  
License Agreements                  
Cash payments       20,000          
Journey | VYNE Product Acquisition                  
License Agreements                  
Sales-based milestone payments paid and payable to date   $ 1,000              
Journey | Emrosi Agreement                  
License Agreements                  
Upfront fees paid         $ 10,000        
Milestone paid   $ 15,000 $ 3,000            
Percentage reduction in royalty payment percentage upon launch of generic competitor         50.00%        
Journey | Vyne Asset Purchase | Cutia Therapeutics (HK) Limited                  
License Agreements                  
Cash payments from Cutia $ 1,000                
Other revenue           $ 600   $ 600  
Minimum | Journey | Emrosi Agreement                  
License Agreements                  
Percentage of royalty on future net sales         10.00%        
Maximum | VYNE Product Acquisition                  
License Agreements                  
Sales-based milestone payments paid and payable to date       450,000          
Maximum | Journey | Emrosi Agreement                  
License Agreements                  
Additional milestones payable         $ 150,000        
Percentage of royalty on future net sales         14.00%        
Annual Sales Of $100 Million | VYNE Product Acquisition                  
License Agreements                  
Revenues       100,000          
Sales-based milestone payments paid and payable to date       10,000          
Annual Sales Of $200 Million | VYNE Product Acquisition                  
License Agreements                  
Revenues       200,000          
Sales-based milestone payments paid and payable to date       20,000          
Annual Sales Of $300 Million | VYNE Product Acquisition                  
License Agreements                  
Revenues       300,000          
Sales-based milestone payments paid and payable to date       30,000          
Annual Sales Of $400 Million | VYNE Product Acquisition                  
License Agreements                  
Revenues       400,000          
Sales-based milestone payments paid and payable to date       40,000          
Annual Sales Of $500 Million | VYNE Product Acquisition                  
License Agreements                  
Revenues       500,000          
Sales-based milestone payments paid and payable to date       $ 50,000